ARKG's concentrated, active bet on pre-revenue biotech gained 32% YTD but lost 13 more percentage points than GNOM over the past five years.
ARKG's $1.4 billion in assets versus GNOM's $75 million gives larger investors meaningfully tighter spreads and better liquidity.
GNOM suits retirement investors as a core holding; ARKG works best as a satellite bet sized to survive another potential 50% drawdown.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener. Both promise pure-play exposure to gene editing, sequencing, and precision medicine, but they differ structurally. One is Cathie Wood's discretionary bet on unprofitable innovators. The other tracks the Solactive Genomics Index and quietly holds Moderna and Vertex next to the moonshots. Over the past year, that structural gap produced a 32.0% year-to-date move in one and a 17.0% move in the other, going in the same direction but at very different speeds.
ARKG is a concentrated wager on pre-revenue and early-revenue platforms. Its top three positions, Twist Bioscience at 9.2%, Tempus AI at 7.6%, and Absci at 7.0%, together make up roughly 23.8% of the portfolio. Gene-editing names account for about 18%, and AI-driven drug discovery adds another 16%. The fund needs cheap capital, risk appetite, and clinical wins to work. Rates falling and biotech M&A reviving are the environment it is built for.
GNOM makes a broader bet. It holds 51 positions, anchored by cash-flowing names: Illumina at 4.6%, Moderna at 4.3%, and Vertex Pharmaceuticals at 3.8%, alongside Bristol-Myers Squibb, Gilead, and AstraZeneca. Passive rebalancing and index reconstitution dilute single-name blowups. The implicit bet is that genomics as a category compounds even if the flashiest names disappoint.
_________________________________
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
Source: Yahoo Finance Top News — This article was automatically imported from the source. Read full article at original source →
